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Abstract
Objective: Biological evidence suggests that inflammation might induce type 2 diabetes (T2D), and epidemiological studies
have shown an association between higher white blood cell count (WBC) and T2D. However, the association has not been
systematically investigated.
Research Design and Methods: Studies were identified through computer-based and manual searches. Previously
unreported studies were sought through correspondence. 20 studies were identified (8,647 T2D cases and 85,040 non-
cases). Estimates of the association of WBC with T2D were combined using random effects meta-analysis; sources of
heterogeneity as well as presence of publication bias were explored.
Results: The combined relative risk (RR) comparing the top to bottom tertile of the WBC count was 1.61 (95% CI: 1.45; 1.79,
p=1.5*10
218). Substantial heterogeneity was present (I
2=83%). For granulocytes the RR was 1.38 (95% CI: 1.17; 1.64,
p=1.5*10
24), for lymphocytes 1.26 (95% CI: 1.02; 1.56, p=0.029), and for monocytes 0.93 (95% CI: 0.68; 1.28, p=0.67)
comparing top to bottom tertile. In cross-sectional studies, RR was 1.74 (95% CI: 1.49; 2.02, p=7.7*10
213), while in cohort
studies it was 1.48 (95% CI: 1.22; 1.79, p=7.7*10
25). We assessed the impact of confounding in EPIC-Norfolk study and
found that the age and sex adjusted HR of 2.19 (95% CI: 1.74; 2.75) was attenuated to 1.82 (95% CI: 1.45; 2.29) after further
accounting for smoking, T2D family history, physical activity, education, BMI and waist circumference.
Conclusions: A raised WBC is associated with higher risk of T2D. The presence of publication bias and failure to control for
all potential confounders in all studies means the observed association is likely an overestimate.
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Introduction
Chronic inflammation, characterized by the increased produc-
tion of cytokines and acute-phase reactants and activation of
inflammatory signalling networks [1–5], may be involved in the
pathogenesis of type 2 diabetes (T2D).Various markers of
inflammation have been shown to predict the future diabetes risk,
including Interleukin-6 (IL-6) and C-reactive protein (CRP)
[1,5].Obesity, a strong risk factor for T2D is also associated with
inflammation as fat tissue releases inflammatory cytokines[6,7].
Inflammation on its own can affect insulin signalling [3], indirectly
increasing the risk of T2D, without the presence of obesity.
Inflammation is also thought to promote beta-cell death [8].
However, there is considerable uncertainty about the direction of
causality of the relationship between inflammation and T2D.
Evidence from epidemiological studies suggests an association
between total peripheral white blood cell (WBC) or leukocyte
count, a non-specific marker of inflammation, and diabetes
risk[9,10]. Although a number of studies have been published,
they have not been systematically reviewed or meta-analysed.
Granulocytes themselves are comprised of neutrophils, basophils
and eosinophils[9]. Little is known about the association of each of
the subfractions with T2D.
In the present study we systematically review and meta-analyse
existing studies of the association between differential WBC count
and T2D, including previously unpublished data from 5,021 cases
and 43,508 non-cases (with 499 cases and 15,051 non-cases from
EPIC-Norfolk study) obtained through correspondence with
investigators. We also explore the potential roles of reverse
causality, publication bias and confounding.
Methods
A. Systematic review and meta-analysis
Bibliographic search, literature review and data
extraction. A bibliographic search was conducted by the first
author to identify all published evidence on the association
between WBC or leukocyte (from now and on, WBC) count and
T2D. The search terms included (‘‘leukocyte’’ OR ‘‘leucocyte
‘‘OR ‘‘white blood’’) combined (AND) with diabetes (diabetes’’
OR ‘‘glucose’’ OR ‘‘metabolic syndrome’’ OR ‘‘hyperglycaemia’’
OR ‘‘hyperglycemia’’). We searched Pubmed 2.0 (National
Library of Medicine) entering each search term as a MeSH, ISI
Web of Knowledge
SM version 4.7 (Thomson Reuters 2009) and
Embase ( 2009 Elsevier B.V.), initially without limits with regard
to publication date or language. Last searches were conducted in
April 2010. Two authors (EGK, ZY) independently reviewed all
identified titles (n=12,705), and subsequently abstracts (n=136)
and full articles (Figure 1). We included evidence from cross-
sectional and prospective cohort studies of adults that used
standard definitions of T2D [11], adjusted for at least age, sex and
BMI (excluded studies n=1). No case-control studies were
identified. For results from the same cohort published more than
once (n=3), we included the study with the largest sample
reported (n=1). We excluded studies of children and adolescents
or with participants who had undergone solid organ or bone
marrow transplantation (Figure 1). Discrepancies in articles
selected for inclusion were addressed by consensus (n=1). We
additionally hand searched reference lists of all articles selected for
inclusion. Two authors (EGK, ZY) extracted information from
each article selected for inclusion including the number of cases
and non-cases, study design and population, measurement of
WBC and diagnosis of T2D, effect estimate and 95% confidence
intervals for associations between WBC, neutrophil/granulocyte,
lymphocyte and monocyte count and T2D risk. Where the risk
ratio (odds ratio, relative risk or hazard ratio) was presented using
other than three groups of WBC, these were converted to compare
the top to bottom tertile of WBC [12].
We identified studies that appeared during the literature review
and did not report on the association between WBC and T2D but
had potentially collected pertinent data, as evident from their
study description. Corresponding authors of these studies (n=19)
were contacted by electronic and regular mail (two electronic
reminders) and invited to submit data using a standardized data
extraction sheet and uniform analysis plan. We requested odds
ratios, relative risks or hazard ratios for the association between
WBC and its sub-fractions where available, comparing top to
bottom tertile of each measure, adjusting for age, sex, smoking,
BMI and waist circumference and using the WHO definition of
diabetes[11]. Data on the number of cases and non-cases and 95%
confidence intervals for the estimated effects were also requested.
We additionally included unpublished results from the EPIC
Norfolk study, described in more detail below, according to the
protocol used for obtaining unpublished evidence from other
investigators.
Meta-analyses. For the purposes of the meta-analysis, we
considered all of odds ratios, risk ratios and hazard ratios as
estimates of the relative risk. These relative risks were combined
across studies using random effects meta-analysis. Heterogeneity
was assessed using the I
2 statistic, which represents the proportion
of variation in the effect sizes that is attributable to genuine
differences across studies rather than to random error [13]. To
identify potential sources of heterogeneity between studies and to
assess the effect of study characteristics on the results, we repeated
the meta-analysis in strata defined by study size, design and
method of data collection and ethnicity of participants. The
between-study variance was used to quantify the degree of
heterogeneity among studies [14]. We also used meta-regression
to estimate the effect of each of the covariates on the relative risk.
Publication bias was assessed using a funnel plot and Begg and
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(version 10.0) statistical software (Stata Corporation, College
Station, Texas, USA). Results were presented in forest plots, where
the sizes of the boxes for individual studies are inversely
proportional to the variances of the log relative risks, and the
horizontal lines represent 95% CIs.
B. EPIC-Norfolk cohort
In addition to including results from the European Prospective
Investigation of Cancer in Norfolk, UK (EPIC-Norfolk) as part of
the overall meta-analysis according to the standard protocol
described above, we used prospective data from this cohort to
investigate the effect of adjusting for a range of potential
confounding factors not consistently available across other studies.
EPIC-Norfolk participants. EPIC-Norfolk is a population-
based cohort study, which has previously been described in detail
[17]. In brief, men and women aged 40 to 79 years were eligible
for participation. In total, 77,630 invitations were sent, 30,447
(39%) individuals consented to take part, with 25,639 (33%)
attending the baseline health check between 1993 and 1997. The
study was approved by the Norfolk Local Research Ethics
Committee and all participants gave written informed consent.
We excluded participants with a history of stroke, myocardial
infarction, or cancer (n=2,460) or prevalent or unconfirmed
diabetes at baseline (n=688).
Measurements. A detailed self-completed health and
lifestyle questionnaire was completed at baseline, including
questions on family history of diabetes, prescribed medications,
occupational social class, smoking status, educational level, and
physical activity assessed by a four point index[17]. Participants
were invited to attend a baseline health check-up at the study clinic
where health checks were carried out by trained research nurses.
Anthropometric measurements were taken according to standard
protocol[17]. Two further health check-ups were performed, after
Figure 1. Information Flow Diagram.
doi:10.1371/journal.pone.0013405.g001
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Since the baseline health-check visit, there were three follow-up
assessments: a postal questionnaire at 18 months, a second health-
check visit (1998–2000), and a further postal questionnaire (2002–
2004).
Biochemical analyses. Biochemical assays were carried out
on samples drawn with participants in the non-fasted state. Blood
samples for WBC measurement were stored overnight at room
temperature and were collected each morning and transported to
the EPIC-Norfolk laboratory in Attleborough (UK). The samples
were analysed in a random order using impedance counting
technique with an MD18 haematology analyser (Coulter
Corporation, Miami, FL, USA). Quality controls were carried
out daily. In addition, the Haematology Department of
Addenbrooke’s Hospital included the EPIC Laboratory in a
monthly quality control scheme. The WBC count coefficient of
variation for the period of study was #3.0%. The standard
deviation values for the differential granulocyte, lymphocyte and
monocyte percentages were less than or equal to 1.5, 1.5, and 3.0,
respectively [18]. Researchers and laboratory personnel did not
have access to identifiable information, and could only identify
samples by number.
Incident type 2 diabetes. Ascertainment of incident cases of
type 2 diabetes involved review of multiple sources of evidence
including self-report (self reported doctor diagnosed diabetes, anti-
diabetic drug use) during follow-up, linkage to primary and
secondary care registers, hospital admissions and mortality
data[17]. Criteria for qualification as a confirmed diabetes case
were: confirmation of self-report by another data source or
diagnosis captured by an external source alone, independently of
participation in study follow-up questionnaires or visit. Possible
cases based solely on self-report and not confirmed by another
data source did not qualify as a confirmed case of diabetes. Cases
not meeting the above criteria were excluded (n=5).
Statistical analysis. Cox proportional hazards regression
was used to estimate hazard ratios for the incidence of diabetes by
tertiles of WBC, granulocyte, lymphocyte, and monocyte count,
using the lowest tertile as the reference category. Results from age
and sex adjusted models were compared to those additionally
adjusting for smoking status (never, former or current), waist
circumference (continuous), BMI (continuous), educational level
(below ‘A’ level vs. ‘A’ level and above where ‘A’ level is school
education to age 18 years), a positive family history of diabetes,
and physical activity level (4 categories ranging from sedentary to
active).
Analyses were restricted to participants with full information on
total WBC, granulocyte, lymphocyte or monocyte count
(n=15,708). We further excluded 158 participants without
complete information on covariates or exclusion criteria.
15,550 participants (499 incident diabetes cases) remained in the
analyses. We calculated a Health Behaviours Score (HBS),
including information on physical activity, alcohol intake, plasma
vitamin C (a biomarker of fruit and vegetable intake) and smoking,
as proposed by Khaw et al [19] and compared models with and
without an interaction term for HBS, using a likelihood ratio test.
All statistical analyses were performed using Stata/SE 10.0
(Stata-Corp, College Station, Texas, USA). All p values were based
on 2-sided tests.
Results
A. Systematic review and meta-analysis
Initial searches identified 12,705 articles and abstracts (Figure 1).
After exclusions, a total of 27 publications were included, 7 of
which reported results on the association between WBC counts
and T2D diabetes risk in a format that could be used[9,10,20–24].
We contacted 19 corresponding authors of the other 20 studies
[25–44] and received data for 13[25,27–29,33,34,36,37,39,40,42–
44]. A total of 6 authors (7 studies) did not respond (n=6) or
declined participation (n=1). Tabular data from one study could
not be used because it was not available in full [27].Our meta-
analysis was therefore based on data from 20 independent studies
(see Figure 1, Table S1 and PRISMA checklist S1), including
EPIC-Norfolk results.
Combined results. The combined relative risk (RR)
comparing the top to bottom tertile of the total WBC count
distributionwas1.61(95%CI:1.45;1.79,p=1.5*10
218).(Figure2).
The combined relative risk was 1.38 (1.17; 1.64, p=1.5*10
24) for
granulocytes, 1.26 (1.02; 1.56, p=0.029) for lymphocytes, and 0.93
(0.68; 1.28, p=0.67) for monocytes, comparing the top to bottom
tertile of the distribution of each measure (Figure 3).
Heterogeneity. For total WBC, there was a high degree of
heterogeneity between the 20 studies (I
2=83%, p,0.001). I
2 was
slightly smaller but still statistically significant among prospective
cohort studies (I
2=74%,p,0.001). Sensitivity analyses were used
to identify potential sources of heterogeneity between studies.
Stratification by study design showed a combined RR for WBC
count of 1.73 (95% CI: 1.49; 2.02, p=7.7*10
213) for prevalent
(5,035 cases; 47,008 non-cases) and 1.48 (95% CI: 1.22; 1.79,
p=7.7*10
25).for incident (3,612 cases; 38,032 non-cases) T2D.
Subgroup analyses (Figure 4) revealed a lower RR in larger ($500
cases) compared to smaller studies (RR 1.43, 95% CI: 1.27;
1.60,p=3.4*10e-9) versus RR 1.85, 95% CI: 1.64; 2.08, p=
3.6*10
225). and no significant difference comparing published to
unpublished evidence included in this report (RR 1.49, 95% CI:
1.23; 1.81, p=5.9*10
25) versus RR 1.72, 95% CI: 1.48; 2.00,
p=1.1*10
212). The combined RR was 1.66 (95% CI 1.48–1.86,
p=2.8*10
218) versus 1.52 (95% CI 1.34–1.73, p=2.02*10
210)
when comparing studies including more than 70% versus less than
70% European descent participants respectively.
Including ethnicity (percentage of participants of European
descent), number of cases, number of participants, source of data
(investigator provided versus published data), and type of study
(prospective cohort versus cross-sectional study or cross sectional
data from a cohort study) in a meta-regression model resulted in a
decrease in the value of I
2 from 83% to 36.0%. The beta-
coefficients and corresponding p values from the meta-regression
models using each of the above parameters in turn are presented
in table 1.
Publication bias. A funnel plot indicated the presence of
publication bias in these studies (Figure 5). Significant publication
bias was also observed using Egger’s bias test (p=0.011 for
prospective cohort and p,0.0001 for cross-sectional studies).
Confounding. Since limited information was available from
the published studies, we were unable to assess the impact of
confounding based on results from published studies. Instead, we
assessed the impact of confounding in the EPIC-Norfolk cohort as
described below.
B. EPIC-Norfolk cohort
We assessed the impact of confounding in EPIC-Norfolk study
participants with detailed covariate information (499 incident
cases, 15,051 non-cases). The following were associated with lower
WBC counts: female sex, lower BMI, lower waist circumference,
lower age, never smoking (Table 2).
Table 3 shows hazard ratios for incident T2D by tertiles of total
WBC and sub-fractions distribution. We decided a priori to include
T2D family history, physical activity and educational level in our
White Blood Cells and Diabetes
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WBC [45–48]. The age and sex adjusted HR for WBC count of
2.19 (95% CI: 1.74; 2.75) was reduced to 1.82 (95% CI: 1.45; 2.29)
after further accounting for smoking status, T2D family history,
physical activity, education, BMI and waist circumference,
comparing the top and bottom tertiles of the total WBC
distribution. Adjusting only for age, sex, smoking, BMI, waist
circumference the HR for WBC count was 1.82 (95% CI 1.44,
2.29), comparing the top and bottom tertiles of the total WBC
distribution.
Analysis within participants with an HbA1c of less than
6.5% at baseline. BaselineHbA1cdatawereavailableforonlya
subset of EPIC-Norfolk (n=9558). 9392 individuals had a baseline
HbA1cof less than 6.5%,166of whom developed incident diabetes.
The age and sex adjusted HR for WBC count of 2.07 (95% CI: 1.41
3.04) was reduced to 1.87 (95% CI: 1.27; 2.76) after further
accounting for smoking status, T2D family history, physical activity,
education, BMI and waist circumference, comparing the top and
bottom tertiles of the total WBC distribution.
Analysis within normal total WBC count limits. When
restricting analyses to individuals with WBC counts within the
normal range (4 to 11*10
9/L) results were similar to when
including participants irrespective of the normal range (as in
Table 3). Comparing the top to bottom tertile of the relevant
distribution, the HR was 1.87 (1.47; 2.39) for total WBC count,
1.45 (1.15–1.83) for granulocytes, 1.73 (1.37–2.17) for lymphocytes
and 1.11 (0.88–1.41) for monocytes.
Analysis with Health Behaviours score (HBS). Given the
associations between WBC and the range of heath behaviours, we
investigated whether associations between WBC count and T2D
differed according to groups defined by adverse versus healthier
lifestyle choices, assuming that unmeasured confounders clustered
according to groups defined by measured behaviours. When
comparing models including HBS, family history of diabetes,
education level, BMI and waist circumference with and without an
interaction term between WBC and HBS, there was no significant
difference between the models, so no evidence of an interaction
was detected (p for interaction 0.21).
Discussion
Summary of Findings
The present meta-analysis includes evidence about the associ-
ation between WBC count and T2D from 20 cross-sectional and
prospective cohort observational studies, comprising a total of
8,647 T2D cases and 85,040 non cases. Total WBC count was
significantly associated with T2D, after adjustment for age, sex,
smoking, BMI, waist circumference. Total granulocyte (and subset
neutrophil) as well as lymphocyte but not monocyte count were
also significantly associated with T2D, after adjustment for age,
sex, smoking, BMI, waist circumference The findings were similar
for incident T2D in the EPIC-Norfolk cohort analysis, where
further adjustment for measured confounders showed the potential
for residual confounding.
Figure 2. Forest plot showing study-specific and combined effect estimates comparing the top to bottom tertile of the WBC count
distribution.
doi:10.1371/journal.pone.0013405.g002
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sub-fractions (Granulocytes include Neutrophils plus Eosinophils plus Basophils).
doi:10.1371/journal.pone.0013405.g003
Figure 4. Forest plot showing combined effect estimates for T2D comparing the top to bottom tertile of the WBC count
distribution. * dotted line representing combined effect estimate for meta-analysis. Size of rhomboids not informative of weight.
doi:10.1371/journal.pone.0013405.g004
White Blood Cells and Diabetes
PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13405The available biological data have strongly suggested that T2D
is an inflammatory disease [1–5].Various markers of inflammation
predict the future diabetes risk, including IL-6, CRP[1], sialic acid,
and orosomucoid[5]. An inflammation score that included the
above four parameters at baseline increased the future T2D risk
almost four fold, when comparing the extreme quintiles in non-
smoking individuals[49]. A recent analysis from the ARIC cohort
showed that WBC, a marker for inflammation, contributed to the
short term increased risk of T2D among participants recently
quitting smoking[50].
We did not find an increased risk of incident T2D for
participants belonging to the higher monocyte tertile. Our findings
agree with the previously reported results of the ARIC study [9].
Several stimuli, including pro-inflammatory as well as metabolic
stimuli increase the recruitment of monocytes to peripheral tissues,
where they differentiate to macrophages and dendritic cells [51].
The destination of monocytes is therefore not the bloodstream and
hence peripheral enumeration is not representative of monocyte
tissue presence or a possible local monocyte-mediated tissue effect.
Possible mechanisms that could link inflammation and diabetes
include interruptions of the insulin signalling in the liver by
inflammatory molecules like IL-6 [52]or a pro-inflammatory effect
on insulin[53], or insulin resistance[54,55]. Obesity, a major risk
factor for diabetes, is a state of chronic inflammation and is
associated with elevated levels of CRP[56], IL-6 [6] and
plasminogen activator inhibitor-1 (PAI-1) [7]. Thus, it is possible
that the association between inflammation and T2D is mediated
by obesity. Studies involving tight matching for obesity suggest
that there is an association between WBC count and insulin
resistance but may be subject to residual confounding[47].In the
Table 1. b coefficients and corresponding p values from the meta-regression models.
Covariate b coefficient P value N of studies
Source of data (tabular vs published paper) 0.144 0.28 20
Type of study (cross-sectional vs longitudinal) 0.164 0.213 20
Number of cases 20.0003 0.018 19*
Number of participants 20.000002 0.89 20
Percentage of Caucasian participants 0.142 0.316 20
*Number of cases not available for one study [60]. b –coefficient represents the change in log relative risk per unit increase in the relevant covariate. Each model includes
each covariate as an explanatory variable and the log relative risk as the outcome variable.
doi:10.1371/journal.pone.0013405.t001
Figure 5. Begg’s Funnel Plot* for visual assessment of the presence of publication bias for all studies included in the meta-analysis
(each study is represented by an open circle). *Tests for Publication Bias. For Prospective Cohort Studies (n=9), Egger’s bias 2.50 (p 0.011). For
Cross-Sectional Studies (n=13), Egger’s bias 2.64 (p,0.001). Overall Egger’s bias p,0.001.
doi:10.1371/journal.pone.0013405.g005
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as BMI to control for confounding associated with obesity. Also,
we investigated possible sources of confounding in this report using
the EPIC-Norfolk study. The observation that the effect size,
adjusted for a wide range of possible confounding factors, was
lower that that adjusted for age and sex alone does suggest the
potential for confounding. Of course, residual confounding by
factors not considered at all or by factors we have considered but
measured imprecisely can not be excluded.
Limitations
Measurement error could affect our assessment of exposures,
outcomes and confounding factors. Differences in the methods
used to measure WBC counts as well as different performance of
the same assays at different time periods might have contributed to
error in longitudinal studies. In general, such measurement error
would attenuate the measure of association if non-differential with
regard to the case status. Some cases of type 1 diabetes (T1D)
might have been inadvertently included; however, such misclas-
sification is likely to have a minimal impact on effect sizes, given
that T1D constitutes only 5–10% of all diabetes cases. Also, given
the ascertainment methods used, misclassification is unlikely in
prospective cohorts; all except three (NHEFS-NHANES I,
NHANES III, Pima Papago Gila River) included incident cases
occurring after age 35 years. The majority of cross-sectional
studies asked about the type of diabetes when assessing prevalent
diabetes or excluded participants using insulin within the first year
of diagnosis.
It is possible that hyperglycaemia itself has an impact on WBC
levels. In people with diabetes, WBC levels are lowered by
treatment with rosiglitazone[57,58] which may be due to the
lowering of glucose levels or an immunomodulatory effect of this
class of drugs. However, similar reductions in WBC have been
observed with other types of glucose lowering drugs including
acarbose[59]. To investigate the possibility of reverse causality,
we compared the difference in strength of the association with
T2D between cross-sectional and prospective cohort studies. The
higher combined RR of WBC in cross-sectional compared
to prospective cohort studies could be suggestive of reverse
causality. However, since the difference between combined RR
between cross-sectional and cohort studies was not statistically
significant and because of evidence of presence of publication
bias, reverse causality is less likely. Moreover, limiting analyses to
healthier people at baseline by excluding participants with a
possible or confirmed history of chronic diseases including T2D
at baseline, and limiting the analysis to individuals with a
baseline HbA1c of less than 6.5%, the risk estimate was almost
identical to that in the entire dataset further decreasing the
attractiveness of a reverse causality hypothesis, at least in the
EPIC-Norfolk cohort.
Results of this study are based on a systematic and
comprehensive literature review, including data from both
prospective cohorts and cross-sectional studies, and previously
unpublished data for a large number of participants. Incomplete
retrieval of available results and studies is possible, since the
studies included were all published in the English language.
Table 2. Distribution of T2D risk factors according to tertiles of total WBC count at baseline, EPIC-Norfolk Study.
Total WBC tertiles 1 (n=5,477) 2 (n=5,120) 3 (n=4,953) P for trend
Tertile range, * 10(9)/L 1–5.8 5.8–7.0 7.1–40.5
Sociodemographic variables
Age, y 57.669.3 58.169.3 58.069.5 0.01
Sex, n (% female) 3,137 (57.3) 2,778 (54.3) 2,677 (54.1) ,0.001
Education level, n (%) 0.004*
‘A’ level{ and above 3,045 (55.6) 2,867 (56.0) 2,622 (52.9)
Below ‘A’ level{ 2,432 (44.4) 2,253 (44.0) 2,331 (47.06)
Anthropometric measures
BMI, Kg/m
2 25.863.6 26.363.8 26.563.8 ,0.001*
Waist circumference, cm 86.3611.9 88.2612.2 89.2612.8 ,0.001*
Health related behaviours
Physical activity level, n (%) ,0.001*
Active 1,107 (20.2) 953(18.6)) 856 (17.3)
Moderately active 1,294 (23.6) 1,157(22.6) 1,084(21.9)
Moderately inactive 1,566(28.6) 1,501 (29.3) 1,346 (27.2)
Inactive 1,510 (27.6) 1,509 (29.5) 1,667 (33.7)
Smoking status, n(%) ,0.001*
Never 2,961 (54.1) 2,417 (47.2) 1,933(39.0)
Former 2,244 (41.0) 2,186 (42.7) 1,939 (39.2)
Current 272 (5.0) 517 (10.1) 1081 (21.8)
Medical history
Family history of diabetes present, n (%) 682(12.5) 676 (13.2) 644 (13.0) 0.32*
1Data are means 6 standard deviation. P values are derived using the Kruskal-Wallis test for continuous variables and the chi-squared test for categorical variables.
{‘A’ level = Advanced Level General Certificate of Education, ‘O’ level = Ordinary Level General Certificate of Education.
*age and sex adjusted.
doi:10.1371/journal.pone.0013405.t002
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language other that English that fitted the inclusion criteria
could be identified. To address variations in design and diabetes
ascertainment we asked corresponding authors to report their
cases following the same diabetes definition (WHO 1999) and
standardize their effect estimates for the same set of covariates
(age, sex, smoking, BMI and waist circumference). Despite these
attempts of standardisation, heterogeneity between investigator
sought studies was not totally eliminated. The funnel plot does
indicate the potential for publication bias despite our efforts to
obtain data that were not published. This could have been due to
the fact that our search strategy, although exhaustive, was more
likely to identify studies with reported results on WBC and T2D
associations. Sensitivity analyses revealed a significantly lower RR
in larger ($500 cases) compared to smaller studies but no
significant difference comparing published to unpublished
evidence.
Summary of conclusions
In summary, these results suggest that WBC is positively
associated with the risk of T2D. However, the presence of
publication bias and failure to control for all potential confounders
in all studies suggests that the observed association may be an
overestimate of the truth. We cannot exclude the possibility of
reverse causality or residual confounding. Approaches such as the
use of genetic determinants of WBC as instrumental variables may
be useful to deal with these as yet unresolved issues.
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